ABO

Tracy Wright, MD is recognized by Continental Who's Who

Retrieved on: 
Saturday, October 2, 2021
Continental, American Glaucoma Society, Research, Harvard University, Diagnosis, ABO, Bascom Palmer Eye Institute, Cataract, Multimedia, Patient, Miami University, MD, Association, American Board of Commissioners for Foreign Missions, Refractive surgery, American Academy of Ophthalmology, Kaiser Permanente, Greenwich Hospital, American Academy, New York University Grossman School of Medicine, Association for Research in Vision and Ophthalmology, DC, COVID-19, Strabismus, American Board of Ophthalmology, Glaucoma, American Society of Cataract and Refractive Surgery, Swimming, District, Time, Yale School of Medicine, Society, Medical device, Medicine, Veterinary medicine

WASHINGTON, Oct. 1, 2021 /PRNewswire/ -- Tracy Wright, MD, is being recognized by Continental Who's Who as a Distinguished Name in Ophthalmology for his excellent work in the Medical field and for his years of professional excellence at Kaiser Permanente.

Key Points: 
  • WASHINGTON, Oct. 1, 2021 /PRNewswire/ -- Tracy Wright, MD, is being recognized by Continental Who's Who as a Distinguished Name in Ophthalmology for his excellent work in the Medical field and for his years of professional excellence at Kaiser Permanente.
  • Tracy Wright, MD, is a highly trained Ophthalmologist specializing in complex glaucoma and treatment for cataracts.
  • Growing up in Tennessee, Dr. Wright knew he wanted to become a doctor from a young age.
  • He worked as a volunteer at a local Boston hospital during his time in college, which encouraged him to go into the medical field.

Ortho Clinical Diagnostics Announces Launch of New ISXM Capabilities

Retrieved on: 
Monday, September 27, 2021
Food, Internet, Blood, Efficiency, Megasphaera, ABO, National Center for Biotechnology Information, Workflow, NASDAQ, Multimedia, Patient, Health, MD, LinkedIn, Hospital, YouTube, IVD, Ortho Clinical Diagnostics, Twitter, Death, Hepatitis C, Food and Drug Administration, Blood transfusion, Antibody, National Center for Health Statistics, COVID-19, Transfusion medicine, Facebook, Chapter Five, Human, Safety, Laboratory, Nasdaq, HIV, NBCI, Medical device, Vaccine, Medicine, Online shopping

RARITAN, N.J., Sept. 27, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (NASDAQ: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced the availability of Immediate Spin Crossmatch (ISXM) on the company's ORTHO VISION® and ORTHO VISION® MAX Analyzers to aid in detecting incompatibility between donors and recipients in blood transfusions.

Key Points: 
  • RARITAN, N.J., Sept. 27, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (NASDAQ: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced the availability of Immediate Spin Crossmatch (ISXM) on the company's ORTHO VISION and ORTHO VISION MAX Analyzers to aid in detecting incompatibility between donors and recipients in blood transfusions.
  • When a full crossmatch is performed, it is required to also complete an ISXM test.
  • Ortho Clinical Diagnostics is powered by Ortho Care Service and Support, a global, award-winning, holistic service and support program designed to empower laboratorians to take full advantage of Ortho's solutions and consistently deliver the highest quality care.
  • Ortho Clinical Diagnostics (Nasdaq: OCDX) is one of the world's largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care.

Ortho Clinical Diagnostics Announces Launch of New ISXM Capabilities

Retrieved on: 
Monday, September 27, 2021
Food, Internet, Blood, Efficiency, Megasphaera, ABO, National Center for Biotechnology Information, Workflow, NASDAQ, Patient, Health, MD, LinkedIn, Hospital, YouTube, IVD, Ortho Clinical Diagnostics, Twitter, Death, Hepatitis C, Food and Drug Administration, Blood transfusion, Antibody, National Center for Health Statistics, COVID-19, Transfusion medicine, Facebook, Chapter Five, Human, Safety, Laboratory, Nasdaq, HIV, NBCI, Medical device, Vaccine, Medicine

RARITAN, N.J., Sept. 27, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (NASDAQ: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced the availability of Immediate Spin Crossmatch (ISXM) on the company's ORTHO VISION® and ORTHO VISION® MAX Analyzers to aid in detecting incompatibility between donors and recipients in blood transfusions.

Key Points: 
  • RARITAN, N.J., Sept. 27, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (NASDAQ: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced the availability of Immediate Spin Crossmatch (ISXM) on the company's ORTHO VISION and ORTHO VISION MAX Analyzers to aid in detecting incompatibility between donors and recipients in blood transfusions.
  • When a full crossmatch is performed, it is required to also complete an ISXM test.
  • Ortho Clinical Diagnostics is powered by Ortho Care Service and Support, a global, award-winning, holistic service and support program designed to empower laboratorians to take full advantage of Ortho's solutions and consistently deliver the highest quality care.
  • Ortho Clinical Diagnostics (Nasdaq: OCDX) is one of the world's largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care.

Milliman analysis: Competitive pricing rate for pension risk transfer costs remains level at 100.1% in August

Retrieved on: 
Wednesday, September 15, 2021
Transfer, Milliman, ABO, City, Research, PRT, Insurance

SEATTLE, Sept. 15, 2021 /PRNewswire/ --Milliman, Inc., a premier global consulting and actuarial firm, today announced the latest results of its Milliman Pension Buyout Index (MPBI).

Key Points: 
  • SEATTLE, Sept. 15, 2021 /PRNewswire/ --Milliman, Inc., a premier global consulting and actuarial firm, today announced the latest results of its Milliman Pension Buyout Index (MPBI).
  • As the Pension Risk Transfer (PRT) market continues to grow, it has become increasingly important to monitor the annuity market for plan sponsors that are considering transferring retiree pension obligations to an insurer.
  • During August, the average estimated cost to transfer retiree pension risk to an insurer remained nearly level, decreasing from 102.3% of a plan's total liabilities to 102.2% of those liabilities.
  • This means the average estimated retiree PRT cost for the month is now 2.2% more than those plans' retiree accumulated benefit obligation (ABO).

Milliman analysis: Competitive pricing rate for pension risk transfer costs increases slightly to 100.1% in July

Retrieved on: 
Wednesday, August 25, 2021
Transfer, Milliman, ABO, PRT, City, Insurance

As the Pension Risk Transfer (PRT) market continues to grow, it has become increasingly important to monitor the annuity market for plan sponsors that are considering transferring retiree pension obligations to an insurer.

Key Points: 
  • As the Pension Risk Transfer (PRT) market continues to grow, it has become increasingly important to monitor the annuity market for plan sponsors that are considering transferring retiree pension obligations to an insurer.
  • Pension risk transactions are on the rise and on track for another record year.
  • During July, the average estimated cost to transfer retiree pension risk to an insurer decreased slightly, from 102.4% of a plan's total liabilities to 102.3% of those liabilities.
  • Meanwhile annuity purchase costs reflecting competition amongst insurers increased slightly, from 100.0% in June to 100.1% in July.

Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA)

Retrieved on: 
Wednesday, July 28, 2021
Health sciences, Life sciences, Pharmaceutical sciences, Pharmacy, Breakthrough therapy, Food and Drug Administration, Pharmaceuticals policy, Regenerative Medicine Advanced Therapy, Biotechnology, Biopharmaceutical, ABO, Therapy

NEW YORK and CLEVELAND, July 28, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company completed a successful Type B meeting with the U.S. Food and Drug Administration (FDA) regarding the pivotal trial to support filing and approval for its AAV-based gene therapy ABO-102 for the treatment of patients with Sanfilippo syndrome type A (MPS IIIA). ABO-102 is currently being evaluated in the single-arm Transpher A study in patients with MPS IIIA.

Key Points: 
  • ABO-102 is currently being evaluated in the single-arm Transpher A study in patients with MPS IIIA.
  • Abeona intends to work closely with the FDA through the regenerative medicine advanced therapy (RMAT) mechanism to assemble the most robust pivotal data package possible for the registration of ABO-102.
  • Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases.
  • The Companys development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need.

'Massively Parallel' Gene Screening Tool Can Accelerate Research for Nearly Any Disease

Retrieved on: 
Friday, March 12, 2021
Autoimmune diseases, Branches of biology, Medical specialties, Genetic epidemiology, Genome-wide association study, ABO, Lupus, Clinical medicine

Up to300,000 peoplein theU.S.have lupus, and the disease causes or contributes toas many as2,000 deaths a year, according to the U.S.Centers for Disease Control and Prevention.

Key Points: 
  • Up to300,000 peoplein theU.S.have lupus, and the disease causes or contributes toas many as2,000 deaths a year, according to the U.S.Centers for Disease Control and Prevention.
  • Longer-term, the successful development of massively parallel gene screening has potential application for finding the genetic connections to virtually any disease.
  • Here's how:
    For nearly two decades, scientists have been using genome-wide association studies(GWAS) to uncover largesetsof clues about gene variations that might be causing a disease.
  • Crucially, the same screening process can be used tosiftsuspected gene association for nearly any complex disease.

New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona’s ABO-102 Gene Therapy

Retrieved on: 
Friday, February 12, 2021
ABO

The interim data was presented in late-breaking platform oral presentations at the 17th Annual WORLDSymposium.

Key Points: 
  • The interim data was presented in late-breaking platform oral presentations at the 17th Annual WORLDSymposium.
  • In addition, the new results from the Transpher B study continue to support ABO-101s biologic activity in patients with MPS IIIB.
  • ABO-102 has been well-tolerated with long-term safety remaining favorable 24-55 months following treatment.
  • We look forward to continued follow-up to assess ABO-101s potential to preserve neurocognitive development in patients with MPS IIIB.

NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials

Retrieved on: 
Wednesday, January 13, 2021
Oncology, Health, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Cancer, Cancer Breakthroughs, Cancer research, Joe Biden, Pancreatic cancer, ABO, Clinical medicine, Medicine, Orphan drugs, Monoclonal antibodies, Pelareorep, ImmunityBio, NantKwest

The early collaborative Cancer Moonshot trials involved the combination of cell therapy and immunotherapeutics from multiple biotech and pharmaceutical companies, including NantKwest, ImmunityBio, Celgene, and Pfizer.

Key Points: 
  • The early collaborative Cancer Moonshot trials involved the combination of cell therapy and immunotherapeutics from multiple biotech and pharmaceutical companies, including NantKwest, ImmunityBio, Celgene, and Pfizer.
  • Based on the data from these trials, ImmunityBio is conducting a pivotal, three-cohort pivotal trial (QUILT 88) in metastatic pancreatic cancer.
  • A randomized Phase 2 study (QUILT 88, Cohorts A and B) for first- and second-line metastatic pancreatic cancer is actively enrolling at three sites.
  • On the basis of our initial studies, we initiated our QUILT 88 randomized trials in metastatic pancreatic cancer and are pleased to present today those findings, including Cohort C survival rates.

DGAP-News: ABO Wind AG specifies further details on announced capital increase

Retrieved on: 
Monday, November 16, 2020
ABO

- Free float increases to up to 38 percent; families of company founders retain majority

Key Points: 
  • - Free float increases to up to 38 percent; families of company founders retain majority
    ABO Wind AG has specified further details regarding the capital increase announced on November 11, 2020 .
  • The Supervisory Board of ABO Wind AG today approved the resolution of the Managing Board to increase the company's share capital by up to a nominal amount of 550,000 euros by issuing up to 550,000 new shares.
  • ABO Wind attaches great importance to a strong financial basis and an equity ratio of at least 40 percent.
  • With the planned capital increase, the free float of the ABO Wind share will grow to up to 38 percent.